CONRATION OF THE PARTIES TO THE CONVENTION
ON BIODIVERSITY SERVING AS THE
MEETING OF THE PARTIES TO THE CARTAGENA
PROTOCOL ON BIOSAFETY
Ninth meeting
Sharm El-Sheikh, Egypt, 17-29 November 2018
Agenda item 17

DECISION ADOPTED BY THE PARTIES TO THE CARTAGENA PROTOCOL ON BIOSAFETY
9/12. Transit and contained use of living modified organisms (Article 6)

The Conference of the Parties serving as the meeting of the Parties to the Cartagena Protocol on
Biosafety,

Recalling decisions BS-V/2, paragraph 1(a), and BS-VII/2, paragraph 2(b),

Also recalling decision CP-VIII/17.

1. Takes note of the assessment by the Compliance Committee of information submitted by
Parties on the Biosafety Clearing-House as decisions under contained use;

2. Reminds Parties that:

(a) Article 3, paragraph (b) of the Protocol sets out the definition of contained use, namely “any
operation, undertaken within a facility, installation or other physical structure, which involves living
modified organisms that are controlled by specific measures that effectively limit their contact with, and their
impact on, the external environment”;

(b) Intentional introduction into the environment can include introduction both for experimental
or for commercial purposes;

(c) A field trial, confined field trial or experimental introduction is to be regarded as intentional
introduction into the environment when the conditions specified in Article 3, paragraph b, of the Protocol
are not met;

3. Also reminds Parties of their obligation under Article 20, paragraph 3(d), and encourages
other Governments to publish in the Biosafety Clearing-House their final decisions regarding the importation
or release of living modified organisms;

4. Encourages Parties, other Governments and relevant organizations to cooperate, share
experiences and promote capacity development to support the implementation of specific measures for
contained use that effectively limit the contact of living modified organisms with, and their impact on, the
external environment, in accordance with Article 3, paragraph (b), of the Protocol.

1 See CBD/CP/MOP/9/2.